A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori

Open source

DOI: 10.1038/s41523-024-00684-w
Published: 2024-08-22
Container: npj Breast Cancer
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41523-024-00684-w,
  title = {A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer},
  author = {Emi Noguchi and Takashi Yamanaka and Hirofumi Mukai and Naohito Yamamoto and Chi-Feng Chung and Yen-Shen Lu and Dwan-Ying Chang and Joohyuk Sohn and Gun Min Kim and Kyung-Hun Lee and Soo-Chin Lee and Tsutomu Iwasa and Hiroji Iwata and Kenichi Watanabe and Kyung Hae Jung and Yuko Tanabe and Seok Yun Kang and Hiroyuki Yasojima and Kenjiro Aogi and Eriko Tokunaga and Sung Hoon Sim and Yoon Sim Yap and Koji Matsumoto and Ling-Ming Tseng and Yoshiko Umeyama and Kazuki Sudo and Yuki Kojima and Tomomi Hata and Aya Kuchiba and Taro Shibata and Kenichi Nakamura and Yasuhiro Fujiwara and Kenji Tamura and Kan Yonemori},
  year = {2024},
  journal = {npj Breast Cancer},
  doi = {10.1038/s41523-024-00684-w},
  url = {https://doi.org/10.1038/s41523-024-00684-w}
}

RIS

TY  - JOUR
TI  - A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
AU  - Emi Noguchi
AU  - Takashi Yamanaka
AU  - Hirofumi Mukai
AU  - Naohito Yamamoto
AU  - Chi-Feng Chung
AU  - Yen-Shen Lu
AU  - Dwan-Ying Chang
AU  - Joohyuk Sohn
AU  - Gun Min Kim
AU  - Kyung-Hun Lee
AU  - Soo-Chin Lee
AU  - Tsutomu Iwasa
AU  - Hiroji Iwata
AU  - Kenichi Watanabe
AU  - Kyung Hae Jung
AU  - Yuko Tanabe
AU  - Seok Yun Kang
AU  - Hiroyuki Yasojima
AU  - Kenjiro Aogi
AU  - Eriko Tokunaga
AU  - Sung Hoon Sim
AU  - Yoon Sim Yap
AU  - Koji Matsumoto
AU  - Ling-Ming Tseng
AU  - Yoshiko Umeyama
AU  - Kazuki Sudo
AU  - Yuki Kojima
AU  - Tomomi Hata
AU  - Aya Kuchiba
AU  - Taro Shibata
AU  - Kenichi Nakamura
AU  - Yasuhiro Fujiwara
AU  - Kenji Tamura
AU  - Kan Yonemori
PY  - 2024
JO  - npj Breast Cancer
DO  - 10.1038/s41523-024-00684-w
UR  - https://doi.org/10.1038/s41523-024-00684-w
ER  -

APA

Noguchi, E., Yamanaka, T., Mukai, H., Yamamoto, N., Chung, C., Lu, Y., Chang, D., Sohn, J., Kim, G. M., Lee, K., Lee, S., Iwasa, T., Iwata, H., Watanabe, K., Jung, K. H., Tanabe, Y., Kang, S. Y., Yasojima, H., Aogi, K., Tokunaga, E., Sim, S. H., Yap, Y. S., Matsumoto, K., Tseng, L., Umeyama, Y., Sudo, K., Kojima, Y., Hata, T., Kuchiba, A., Shibata, T., Nakamura, K., Fujiwara, Y., Tamura, K., & Yonemori, K. (2024). A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. npj Breast Cancer. https://doi.org/10.1038/s41523-024-00684-w

Source records

crossref · retrieved 2026-09-25T14:24:48.426Z